5 Amendments of Stanislav POLČÁK related to 2021/2132(DEC)
Amendment 16 #
Draft opinion
Paragraph 15 a (new)
Paragraph 15 a (new)
15a. Highlights the importance of involving the relevant stakeholders, such as representatives of health professionals, of patients and of other parties, in the light of the alarming prevalence of disinformation regarding the COVID-19 pandemic in the conversation on protection of public health and calls on the EMA to continue the development of this conversation as actively as possible, based on the latest scientific knowledge;
Amendment 17 #
Draft opinion
Paragraph 15 b (new)
Paragraph 15 b (new)
15b. Welcomes the fact that tackling increasing antimicrobial resistance (in particular through supporting the development of new medicines, collecting data on veterinary antimicrobial consumption and promoting responsible use of such medicines) remains one of the EMA’s priorities, even in the light of the current situation;
Amendment 18 #
Draft opinion
Paragraph 15 c (new)
Paragraph 15 c (new)
15c. Emphasises that the COVID-19 pandemic is impacting all aspects of health care, including the availability of medicines due to supply chain disruptions; considers that the situation has only served to highlight the need, of which we were already aware, to ensure the highest possible level of self- sufficiency in the development and production of medicines within the European Union; welcomes the EMA’s commitment to continue contributing to the development and strengthening of the European Union’s response system in the event of reduced availability of medicines;
Amendment 19 #
Draft opinion
Paragraph 15 d (new)
Paragraph 15 d (new)
15d. Welcomes the level of assistance that the EMA has provided to companies developing vaccines and medicines against COVID-19; lauds its consistently scientific approach, which places the health of EU citizens above all else;
Amendment 20 #
Draft opinion
Paragraph 15 e (new)
Paragraph 15 e (new)
15e. Welcomes the EMA’s efforts to increase the level of transparency of its decision-making, as evidenced, for example, by the publication of data from clinical trials submitted in the marketing authorisation process for COVID-19 medicines or the increased level of communication with the media and the public; feels that this transparent approach is crucial in the current situation;